The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSMD.L Regulatory News (SMD)

  • There is currently no data for SMD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Mediscience Award Win

17 Jun 2022 10:40

RNS Number : 2898P
Spectral MD Holdings, Ltd.
17 June 2022
 

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company" or the Group")

 

Mediscience Award Win

Spectral MD win Best Technology award at the European Mediscience Awards

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that it has won the Best Technology award at the European Mediscience Awards, held at Hotel InterContinental, London, last night.

 

The Best Technology award is awarded for a technology that is innovative, well funded, and capable of significant commercial success even if it is not yet proven. The technology concerned could have been developed within the organization or acquired. Spectral MD received the award for its DeepView® Wound Imaging System, a predictive analytics platform that combines AI algorithms and medical imaging for wound prediction.

The European Mediscience Awards is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe, bringing together the best European mediscience companies to celebrate achievement and recognise success.

Wensheng Fan, Chief Executive Officer of Spectral MD, commented: "I was delighted to collect this award last night on behalf of the Spectral MD team. This award is a testament to the passion and hard work of the Spectral MD team and the fantastic technology that we continue to develop. We are honored to be recognized on an international stage at such a prestigious event."

 

For further information please contact:

 

Spectral MD Holdings, Ltd.

investors.spectralmd.com

Wensheng Fan, Chief Executive Officer

via Walbrook PR

Nils Windler, Chief Financial Officer

 

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com

Paul McManus / Sam Allen

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

+44 (0)7407 804 654

 

 

About Spectral MD:

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUBOKRUKUNARR
12
Date   Source Headline
7th Sep 20232:22 pmRNSResult of Rosecliff Special Meeting - Correction
7th Sep 202311:36 amRNSResult of Rosecliff Special Meeting
31st Aug 20234:35 pmRNSResult of General Meeting
25th Aug 20237:00 amRNSExercise of Options
17th Aug 20235:01 pmRNSPosting of Circular and Notice of General Meeting
16th Aug 20231:00 pmRNSInvestor Video Published
14th Aug 202311:30 amRNSProxy Statement & Prospectus Mailed by Rosecliff
14th Aug 20237:00 amRNSISO 13485 Certification Received
11th Aug 20234:10 pmRNSUpdated Form S-4 Filing & Investor Presentation
9th Aug 20234:05 pmRNSUpdated Form S-4 Filed by Rosecliff
9th Aug 20232:50 pmRNSProposed AIM Cancellation
1st Aug 20237:01 amRNSForm 8-K Filed by Rosecliff
1st Aug 20237:00 amRNSUpdated Investor Presentation & Rosecliff Filing
28th Jul 202312:58 pmRNSUpdated Form S-4 Filed by Rosecliff
28th Jun 20237:00 amRNSUpdated Form S-4 Filed by Rosecliff
22nd Jun 20237:00 amRNSNew Investor Presentation & Filing by Rosecliff
20th Jun 20237:00 amRNSISO 13485 Certification Audit Completed
13th Jun 20237:00 amRNSStudy Results Published in Peer-Reviewed Journal
1st Jun 20237:00 amRNSBlock Listing Six Monthly Return
2nd May 20231:06 pmRNSFiling of Form S-4 by Rosecliff
19th Apr 20237:00 amRNSForm 8-K Filed by Rosecliff Acquisition Corp I
18th Apr 20237:00 amRNS$4.0 Million Grant Award from the MTEC
13th Apr 20237:00 amRNSGrant of Options
11th Apr 20237:00 amRNSBusiness Combination Agreement
29th Mar 20237:00 amRNSPublication of Annual Financial Report
27th Mar 20237:00 amRNSU.S. Burn AI Training Study Enrollment Completed
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
27th Feb 20237:00 amRNSFinal Results
21st Feb 20237:00 amRNSEU Clinical Study Initiated
14th Feb 202310:18 amRNSNotice of Results
3rd Feb 20234:24 pmRNSTotal Voting Rights
18th Jan 20237:00 amRNSDFU Clinical Study Interim Results & Burn Update
16th Jan 20237:00 amRNSTrading Update
9th Nov 20227:00 amRNSAppointment of Chief Operating Officer
7th Nov 20227:00 amRNSBlock Admission
2nd Nov 20227:00 amRNSTrading Update
24th Oct 20227:00 amRNSChanges to Board of Directors
12th Oct 20223:26 pmRNSExercise of Options
5th Oct 20227:00 amRNSBurn Image Assessment Study (“BIAS”) Results
27th Sep 20225:59 pmRNSResult of AGM
20th Sep 20227:00 amRNSInterim results for the six-months to 30 June 2022
12th Sep 20221:00 pmRNSChange of Interim Results Date
5th Sep 20227:00 amRNSNotice of results
1st Sep 20227:00 amRNSNotice of AGM
30th Aug 20227:00 amRNSAdditional $8.2M of Funding from BARDA
19th Aug 20229:13 amRNSGrant of Options
7th Jul 20227:00 amRNSStockholder waiver granted
23rd Jun 20227:00 amRNSRemoval of Regulation S restrictions
17th Jun 202210:40 amRNSMediscience Award Win
13th Jun 20227:00 amRNSInitiation of DFU Validation Study
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.